Alzamend Neuro Inc. (ALZN)
0.68
-0.02 (-2.94%)
At close: Apr 25, 2025, 3:58 PM
0.68
0.13%
After-hours: Apr 25, 2025, 04:13 PM EDT
-2.94% (1D)
| Bid | 0.65 |
| Market Cap | 4.49M |
| Revenue (ttm) | 76.11K |
| Net Income (ttm) | -4.23M |
| EPS (ttm) | -134.51 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.57 |
| Analyst | Buy |
| Ask | 0.8 |
| Volume | 38,732 |
| Avg. Volume (20D) | 381,637 |
| Open | 0.68 |
| Previous Close | 0.70 |
| Day's Range | 0.68 - 0.71 |
| 52-Week Range | 0.64 - 15.06 |
| Beta | -0.19 |
About ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neu...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ALZN
Website https://www.alzamend.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ALZN stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 2841.18% from the latest price.
Stock Forecasts1 month ago
+5.03%
Alzamend Neuro shares are trading higher after the...
Unlock content with
Pro Subscription
8 months ago
+186.76%
Alzamend Neuro shares are trading higher after the company announced that it is partnering with Massachusetts General Hospital as its contract research organization to conduct first of its kind Phase II clinical study of AL001 for treatment of patients with PTSD.
